A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations Under Fasted and Fed Conditions in Healthy Participants
Latest Information Update: 28 Apr 2022
Price :
$35 *
At a glance
- Drugs Emraclidine (Primary) ; Emraclidine (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 25 Apr 2022 Status changed from recruiting to completed.
- 10 Jan 2022 Status changed from not yet recruiting to recruiting.
- 09 Nov 2021 New trial record